TAMOXIFEN ENHANCES THE CYTOTOXIC EFFECTS OF THE NITROSOUREA FOTEMUSTINE - RESULTS ON HUMAN-MELANOMA CELL-LINES

被引:0
作者
FISCHEL, JL
BARBE, V
BERLION, M
FORMENTO, P
BERRILE, J
BIZZARI, JP
MILANO, G
机构
[1] CTR ANTOINE LACASSAGNE,36 VOIE ROMAINE,F-06054 NICE,FRANCE
[2] LABS SERVIER,F-92145 COURBEVOIE,FRANCE
关键词
FOTEMUSTINE; TAMOXIFEN; 4 OH TAMOXIFEN; MELANOMA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fotemustine (Fote) is a new aminoacid linked chloroethyl nitrosourea which has been shown to be useful in disseminated malignant melanoma. The aim of the present study was to analyze the cytotoxic effects resulting from the combination of antiestrogens and Fote on human melanoma cell lines. The antiestrogens tested were tamoxifen (TMX 5.10(-7) M and 5.10(-6) M) and 40H TMX (5.10(-8) M and 5.10(-7) M). As a preliminary step, a series of nine human melanoma cell lines was screened in order to identify and quantify the presence of estradiol receptors (ER) in these cell lines. This led to selecting an ER positive (+) cell line. The drugs alone or in combination were then tested against CAL 1 ER (+) and CAL 7 ER (-) melanoma cell lines. Different sequences of drug combinations were tested using clinically compatible drug concentrations. For CAL I cells there was a growth inhibitory effect induced by the antiestrogens given alone. Overall, the presence of the antiestrogens resulted in higher cytotoxic effects than when cells were exposed to Fote alone. The lowest IC50 Fote values as compared to Fote alone were generated by the sequences with the antiestrogens administered before Fote. Significantly, these associations with antiestrogens enabled the IC50 values of Fote to be reduced up to 80%. Globally TMX and 40H TMX had similar synergistic effects. TMX and 40H TMX had a modest influence on Fote cytotoxic effects against CAL 7 ER (-) cells. These data may be useful for optimal planning of future clinical trials for malignant melanoma using antiestrogens and nitrosoureas.
引用
收藏
页码:599 / 604
页数:6
相关论文
共 26 条
  • [1] MULTICENTER PHASE-II TRIAL OF THE SINGLE AGENT FOTEMUSTINE IN PATIENTS WITH ADVANCED MALIGNANT-MELANOMA
    CALABRESI, F
    AAPRO, M
    BECQUART, D
    DIRIX, L
    WILS, J
    ARDIZZONI, A
    GERARD, B
    [J]. ANNALS OF ONCOLOGY, 1991, 2 (05) : 377 - 378
  • [2] CARMICHAEL J, 1987, CANCER RES, V47, P936
  • [3] REVERSAL OF ACQUIRED-RESISTANCE TO ADRIAMYCIN IN CHO CELLS BY TAMOXIFEN AND 4-HYDROXY TAMOXIFEN - ROLE OF DRUG-INTERACTION WITH ALPHA-1 ACID GLYCOPROTEIN
    CHATTERJEE, M
    HARRIS, AL
    [J]. BRITISH JOURNAL OF CANCER, 1990, 62 (05) : 712 - 717
  • [4] REDUCTION OF THE MEMBRANE FLUIDITY OF HUMAN BREAST-CANCER CELLS BY TAMOXIFEN AND 17-BETA-ESTRADIOL
    CLARKE, R
    VANDENBERG, HW
    MURPHY, RF
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (21) : 1702 - 1705
  • [5] TREATMENT OF METASTATIC MALIGNANT-MELANOMA WITH DACARBAZINE PLUS TAMOXIFEN
    COCCONI, G
    BELLA, M
    CALABRESI, F
    TONATO, M
    CANALETTI, R
    BONI, C
    BUZZI, F
    CECI, G
    CORGNA, E
    COSTA, P
    LOTTICI, R
    PAPADIA, F
    SOFRA, MC
    BACCHI, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (08) : 516 - 523
  • [6] STEROID-RECEPTORS IN HUMAN OSTEOBLAST-LIKE CELLS
    ETIENNE, MC
    FISCHEL, JL
    MILANO, G
    FORMENTO, P
    FORMENTO, JL
    FRANCOUAL, M
    FRENAY, M
    NAMER, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1990, 26 (07) : 807 - 810
  • [7] TAMOXIFEN METABOLISM - PHARMACOKINETIC AND INVITRO STUDY
    ETIENNE, MC
    MILANO, G
    FISCHEL, JL
    FRENAY, M
    FRANCOIS, E
    FORMENTO, JL
    GIOANNI, J
    NAMER, M
    [J]. BRITISH JOURNAL OF CANCER, 1989, 60 (01) : 30 - 35
  • [8] FISCHER RI, 1976, LANCET, V2, P337
  • [9] TAMOXIFEN-CITRATE COUNTERACTS THE ANTITUMOR EFFECTS OF CYTO-TOXIC DRUGS INVITRO
    HUG, V
    HORTOBAGYI, GB
    DREWINKO, B
    FINDERS, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (12) : 1672 - 1677
  • [10] LEGHA SS, 1989, SEMIN ONCOL, V16, P34